CYTK vs MDGL vs KRYS vs RCUS vs ACAD

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Cytokinetics, Incorporated (CYTK) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 9x versus Krystal Biotech, Inc. at 43. 4x. On forward P/E, Krystal Biotech, Inc. is actually cheaper at 39. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +319. 2%, compared to -18. 6% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: MDGL returned +39. 2% versus ACAD's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Madrigal Pharmaceuticals, Inc.

(MDGL) is the lower-risk stock at 0. 57β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 245% more volatile than MDGL relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 59% for Madrigal Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to -24. 3% for Cytokinetics, Incorporated. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus -891. 6% for Cytokinetics, Incorporated — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -695. 4% for CYTK. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Krystal Biotech, Inc.

(KRYS) trades at 39. 3x forward P/E versus 50. 9x for ACADIA Pharmaceuticals Inc. — 11. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACAD: 54. 1% to $34. 78.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cytokinetics, Incorporated (CYTK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), +817. 2% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CYTK: +817. 2%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the null sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CYTK is a small-cap high-growth stock; MDGL is a mid-cap high-growth stock; KRYS is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.